RBM20 Condensate Screening via Fluorescent Cellular Models
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are hindered in effectively screening and identifying compounds that modulate RBM20-associated cellular processes due to the unclear role of RBM20 in disease presentation and progression, particularly in conditions like Dilated Cardiomyopathy, where mutant RBM20 polypeptides lead to aberrant molecular processes and disease development.
Innovation Solution
A method involving the admixture of compounds with cellular models expressing RBM20 polypeptides to assess modulation of characteristics such as location, distribution, number, size, and functional activity of RBM20 condensates, allowing for the identification of compounds that reduce RBM20 condensate formation or activity in the cytoplasm, thereby potentially treating associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional screening methods are used to identify compounds modulating RBM20-associated processes, then the screening process can be performed with existing techniques, but the effectiveness is hindered due to unclear understanding of RBM20 role in disease
Solution Approach 1:
The patent segments the complex RBM20-associated cellular processes into specific measurable characteristics including condensate formation, location, distribution, number, size, and functional activity. This segmentation allows for targeted screening of compounds that modulate these specific parameters, thereby improving screening effectiveness despite limited understanding of overall RBM20 disease role
Solution Approach 2:
The patent employs fluorescent tagging of RBM20 polypeptides to enable visual detection and measurement of condensate characteristics. This optical approach allows researchers to observe and quantify condensate formation, location, and other characteristics directly, providing the necessary information to effectively screen for modulating compounds
2Adaptability or versatility
If cellular models expressing RBM20 polypeptides are used to screen compounds, then compounds can be identified that modulate RBM20 condensate characteristics, but the complexity of the screening system increases
Solution Approach 1:
The patent creates a universal screening platform using cellular models that express fluorescently-tagged RBM20 polypeptides. This platform can simultaneously assess multiple characteristics (condensate formation, location, distribution, number, size, and functional activity) and can be applied to screen for compounds targeting different aspects of RBM20 pathology, thereby providing versatile compound identification capability
Solution Approach 2:
The patent introduces fluorescent tags as intermediaries that bridge the gap between RBM20 polypeptides and detection systems. These fluorescent tags enable indirect observation and measurement of condensate characteristics through optical methods, simplifying the overall detection process while maintaining the ability to gather comprehensive information about condensate properties
Data Source
AI summary
The present disclosure, in some aspects, is directed to methods for screening and identifying compounds that modulate one or more characteristics associated with a condensate comprising a RBM20 polypeptide and/or the RBM20 polypeptide. In other aspects, the disclosure is directed to systems and composition components thereof, such as cellular models useful for the methods described herein.